Ascelia Pharma AB (publ) (ACE.ST)
SEK 3.1
(-2.36%)
SEK 3.1
(-2.36%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -110.91 Million SEK | 24.55% |
| 2022 | -147 Million SEK | -6.57% |
| 2021 | -137.94 Million SEK | -47.65% |
| 2020 | -93.42 Million SEK | -154.27% |
| 2019 | -36.74 Million SEK | 1.73% |
| 2018 | -37.39 Million SEK | -51.3% |
| 2017 | -24.71 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -17.05 Million SEK | -42.64% |
| 2024 Q2 | -11.3 Million SEK | 33.56% |
| 2023 Q1 | -36.7 Million SEK | 29.64% |
| 2023 Q4 | -11.95 Million SEK | 44.04% |
| 2023 FY | -111.47 Million SEK | 24.17% |
| 2023 Q2 | -41.79 Million SEK | -13.85% |
| 2023 Q3 | -21.36 Million SEK | 48.88% |
| 2022 Q2 | -32.65 Million SEK | -0.25% |
| 2022 Q1 | -32.57 Million SEK | 16.83% |
| 2022 FY | -147 Million SEK | -6.57% |
| 2022 Q3 | -29.61 Million SEK | 9.29% |
| 2022 Q4 | -52.16 Million SEK | -76.13% |
| 2021 Q1 | -33.74 Million SEK | -21.02% |
| 2021 FY | -137.94 Million SEK | -47.65% |
| 2021 Q2 | -32.31 Million SEK | 4.23% |
| 2021 Q3 | -32.73 Million SEK | -1.31% |
| 2021 Q4 | -39.16 Million SEK | -19.62% |
| 2020 FY | -93.42 Million SEK | -154.27% |
| 2020 Q2 | -28.6 Million SEK | -38.46% |
| 2020 Q4 | -27.87 Million SEK | -71.11% |
| 2020 Q3 | -16.29 Million SEK | 43.03% |
| 2020 Q1 | -20.65 Million SEK | 9.96% |
| 2019 Q2 | -14.49 Million SEK | -23.76% |
| 2019 Q1 | -11.71 Million SEK | -61.67% |
| 2019 FY | -36.74 Million SEK | 1.73% |
| 2019 Q4 | -22.94 Million SEK | -65.27% |
| 2019 Q3 | -13.88 Million SEK | 4.22% |
| 2018 Q1 | -4.4 Million SEK | 52.78% |
| 2018 FY | -37.39 Million SEK | -51.3% |
| 2018 Q2 | -8.18 Million SEK | -85.55% |
| 2018 Q3 | -3.94 Million SEK | 51.77% |
| 2018 Q4 | -7.24 Million SEK | -83.55% |
| 2017 FY | -24.71 Million SEK | 0.0% |
| 2017 Q4 | -9.33 Million SEK | -54.05% |
| 2017 Q3 | -6.06 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -248.98 Million SEK | 55.453% |
| Ziccum AB (publ) | -21.56 Million SEK | -414.443% |
| Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | -576.264% |
| BioArctic AB (publ) | 252.64 Million SEK | 143.902% |
| Sprint Bioscience AB (publ) | -845 Thousand SEK | -13025.917% |
| Mendus AB (publ) | -100.65 Million SEK | -10.198% |
| Genovis AB (publ.) | 54.22 Million SEK | 304.548% |
| Intervacc AB (publ) | -93.57 Million SEK | -18.524% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | -615.021% |
| Active Biotech AB (publ) | -46.48 Million SEK | -138.607% |
| Magle Chemoswed Holding AB (publ) | 18 Million SEK | 715.881% |
| Bio-Works Technologies AB (publ) | -55.41 Million SEK | -100.144% |
| Aptahem AB (publ) | -10.1 Million SEK | -997.641% |
| Vicore Pharma Holding AB (publ) | -321.5 Million SEK | 65.502% |
| Kancera AB (publ) | -65.04 Million SEK | -70.527% |
| Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | 17.608% |
| Fluicell AB (publ) | -26.87 Million SEK | -312.642% |
| Saniona AB (publ) | -81.06 Million SEK | -36.821% |
| Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | -796.565% |
| Biovica International AB (publ) | -126.07 Million SEK | 12.024% |
| Spago Nanomedical AB (publ) | -42.5 Million SEK | -160.943% |
| AcouSort AB (publ) | -17.48 Million SEK | -534.265% |
| Xintela AB (publ) | -57.23 Million SEK | -93.777% |
| Abliva AB (publ) | -96.54 Million SEK | -14.88% |
| Egetis Therapeutics AB (publ) | -324.8 Million SEK | 65.852% |
| Karolinska Development AB (publ) | -3.5 Million SEK | -3064.451% |
| OncoZenge AB (publ) | -15.9 Million SEK | -597.485% |
| Amniotics AB (publ) | -29.07 Million SEK | -281.502% |
| 2cureX AB (publ) | -36.36 Million SEK | -205.019% |
| CombiGene AB (publ) | -36.3 Million SEK | -205.505% |
| Asarina Pharma AB (publ) | -14.64 Million SEK | -657.609% |
| Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 71.146% |
| Camurus AB (publ) | 532.35 Million SEK | 120.835% |
| Corline Biomedical AB | -1.78 Million SEK | -6103.244% |
| IRLAB Therapeutics AB (publ) | -180.76 Million SEK | 38.642% |
| Isofol Medical AB (publ) | -41.68 Million SEK | -166.089% |
| I-Tech AB | 24.43 Million SEK | 553.914% |
| Hansa Biopharma AB (publ) | -788.49 Million SEK | 85.933% |
| Cyxone AB (publ) | -21.66 Million SEK | -412.045% |
| ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | -4.67% |
| Biosergen AB | -27.26 Million SEK | -306.8% |
| Cantargia AB (publ) | -290.01 Million SEK | 61.756% |
| NextCell Pharma AB | -43.17 Million SEK | -156.911% |
| Xspray Pharma AB (publ) | -180.76 Million SEK | 38.642% |
| Elicera Therapeutics AB (publ) | -17.09 Million SEK | -548.761% |
| Nanologica AB (publ) | -69.96 Million SEK | -58.532% |
| SynAct Pharma AB | -224.49 Million SEK | 50.594% |
| Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | -151.073% |
| Stayble Therapeutics AB (publ) | -23.95 Million SEK | -363.024% |
| LIDDS AB (publ) | -40.67 Million SEK | -172.69% |
| Lipum AB (publ) | -37.25 Million SEK | -197.724% |
| BioInvent International AB (publ) | -369.94 Million SEK | 70.019% |
| Alzinova AB (publ) | -16.52 Million SEK | -571.311% |
| Oncopeptides AB (publ) | -253.44 Million SEK | 56.238% |
| Pila Pharma AB (publ) | -6.39 Million SEK | -1634.861% |
| Guard Therapeutics International AB (publ) | -115.07 Million SEK | 3.614% |
| Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | -450.742% |
| Simris Alg AB (publ) | -36.63 Million SEK | -202.754% |
| Diamyd Medical AB (publ) | -146.56 Million SEK | 24.325% |
| Xbrane Biopharma AB (publ) | -310.42 Million SEK | 64.27% |
| Diagonal Bio AB (publ) | -11.56 Million SEK | -858.966% |